Stock data
Aytu BioPharma, Inc. (AYTU)
Aytu BioPharma, Inc. (AYTU) reported revenue of US$57.57M and net income of -US$14.25M for fiscal 2026. The figures below come from the company's SEC filings.
Annual results
Data as of 2026-06-30
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | US$57.57M | US$36.82M | -US$8.31M | -US$14.25M | — |
| 2025 | US$66.38M | US$45.83M | -US$7.83M | -US$13.56M | — |
| 2024 | US$65.18M | US$49.05M | -US$1.59M | -US$15.84M | — |
| 2023 | US$107.40M | US$66.63M | -US$17.07M | -US$17.05M | — |
| 2022 | US$96.67M | US$52.28M | -US$109.91M | -US$108.78M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$16.11M | -US$0.01M | — |
| 2026-03-31 | US$12.41M | -US$5.62M | — |
| 2025-12-31 | US$15.16M | -US$10.58M | — |
| 2025-09-30 | US$13.89M | US$1.97M | — |
| 2025-06-30 | US$15.13M | -US$19.82M | — |
| 2025-03-31 | US$18.45M | US$3.99M | — |
| 2024-12-31 | US$16.22M | US$0.79M | — |
| 2024-09-30 | US$16.57M | US$1.47M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.